for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dr.Reddy's Laboratories Ltd

REDY.BO

Latest Trade

2,726.05INR

Change

-7.95(-0.29%)

Volume

7,157

Today's Range

2,712.65

 - 

2,749.20

52 Week Range

2,065.30

 - 

2,965.20

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

Nuvo Pharmaceuticals - U.S. Court Denied Motion For Summary Judgment Filed By Dr. Reddy's Laboratories

Nov 11 (Reuters) - Nuvo Pharmaceuticals Inc <NRI.TO>::NUVO PHARMACEUTICALS INC - UNITED STATES COURT DENIED A MOTION FOR SUMMARY JUDGMENT FILED BY DR. REDDY'S LABORATORIES.NUVO PHARMACEUTICALS INC - PATENT INFRINGEMENT LITIGATION AGAINST DRL WILL CONTINUE.NUVO PHARMACEUTICALS INC - PARTIES MUTUALLY AGREED ON A PRE-TRIAL LITIGATION SCHEDULE WITH COURT THROUGH TO APRIL 2021.NUVO PHARMACEUTICALS - WHILE LITIGATION IS PENDING, DRL MAY STILL LAUNCH GENERIC VERSION OF VIMOVO "AT RISK" UPON APPROVAL BY U.S. FDA.NUVO PHARMA - IF "AT RISK" LAUNCH OCCURS, NUVO IRELAND AND U.S. PARTNER CAN CONTINUE TO ENFORCE '996 & '920 PATENTS AGAINST DRL & SEEK DAMAGES.

India's Dr.Reddy's Laboratories Sept-Qtr Consol Net Pat Rises

Nov 1 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::SEPT QUARTER CONSOL PROFIT 10.92 BILLION RUPEES VERSUS PROFIT OF 5.04 BILLION RUPEES YEAR AGO.CONSENSUS FORECAST FOR SEPT QUARTER CONSOL PROFIT WAS 6 BILLION RUPEES.SEPT QUARTER CONSOL REVENUE 48 BILLION RUPEES VERSUS 37.98 BILLION RUPEES LAST YEAR.SEPT QUARTER CONSOL NET PAT (IND AS) 11.07 BILLION RUPEES VERSUS PROFIT OF 5.18 BILLION RUPEES YEAR AGO.SEPT QUARTER CONSOL NET SALES (IND AS) 39.98 BILLION RUPEES VERSUS 36.87 BILLION RUPEES LAST YEAR.

Dr.Reddy's Labs Gets US FDA EIR For Shreveport, Louisiana Facility

Oct 23 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::GOT EIR FOR FORMULATIONS MANUFACTURING FACILITY AT SHREVEPORT, LOUISIANA, USA.REPORT INDICATING CLOSURE OF INSPECTION OF FACILITY IS DETERMINED AS NO ACTION INDICATED (NAI).

Dr.Reddy's Laboratories Confirms Its Voluntary Nationwide Recall Of All Ranitidine Products In U.S. Market

Oct 23 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::DR.REDDY'S LABORATORIES LTD SAYS CONFIRMS ITS VOLUNTARY NATIONWIDE RECALL OF ALL RANITIDINE PRODUCTS IN U.S. MARKET.

Dr.Reddy's Labs Launches Of Generic Prevacid Capsules In U.S. Market

Sept 16 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::LAUNCH OF OVER-THECOUNTER, STORE-BRAND EQUIVALENT OF PREVACID 24HR CAPSULES IN THE U.S. MARKET.

India's Dr. Reddy's Receives FDA EIR After Audit At Visakhapatnam Plant

Sept 12 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::SAYS RECEIVED EIR FROM US FDA AFTER AUDIT AT DUVVADA, VISAKHAPATNAM PLANT.

Dr.Reddy's Laboratories Launches Bupropion Hydrochloride Extended-Release Tablets In U.S.

Sept 5 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::LAUNCHES BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP (SR) IN U.S. MARKET.

Dr.Reddy's Issued Form 483 With 8 Observations Post Audit Of Duvvada Formulations Manufacturing Plant

Aug 20 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::AUDIT OF DUVVADA FORMULATIONS MANUFACTURING PLANT BY USFDA COMPLETED; CO ISSUED FORM 483 WITH 8 OBSERVATIONS.

Dr.Reddy's Laboratories Launches Versavo In India

Aug 19 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::ANNOUNCES LAUNCH OF VERSAVO (BEVACIZUMAB BIOSIMILAR) IN INDIA.

Eli Lilly Says U.S. Court Of Appeals Rules In Favor Of Co In Alimta Alternate Salt Form Patent Lawsuit

Aug 9 (Reuters) - Eli Lilly and Co <LLY.N>::U.S. COURT OF APPEALS RULES IN FAVOR OF LILLY IN ALIMTA ALTERNATE SALT FORM PATENT LAWSUIT.RULING CAME IN APPEALS OF U.S. DISTRICT COURT DECISIONS IN CASES OF CO V. DR. REDDY'S LABORATORIES AND CO V. HOSPIRA.IF PATENT IS ULTIMATELY UPHELD THROUGH ALL REMAINING CHALLENGES, ALIMTA WOULD MAINTAIN U.S. EXCLUSIVITY UNTIL MAY 2022.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up